Prismaflex ST150 versus M150 in different treatment's conditions
| ISRCTN | ISRCTN95194850 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN95194850 |
| Secondary identifying numbers | 1465 |
- Submission date
- 03/02/2009
- Registration date
- 24/02/2009
- Last edited
- 24/02/2009
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Urological and Genital Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Prof Marie Schetz University Hospital Gasthuisberg
Scientific
Scientific
Dept of Intensive Care
Herestraat 49
Leuven
3000
Belgium
Study information
| Study design | Prospective randomised cross-over study |
|---|---|
| Primary study design | Interventional |
| Secondary study design | Randomised controlled trial |
| Study setting(s) | Hospital |
| Study type | Treatment |
| Participant information sheet | Not available in web format, please use the contact details below to request a patient information sheet |
| Scientific title | Prismaflex ST150 versus M150 in different treatment's conditions: a prospective randomised cross-over study |
| Study objectives | To validate the conclusion of a previous study: 'AN69 surface treated (ST) versus AN69 in continuous renal replacement therapy (CRRT): a prospective randomised cross-over study without heparin in the extracorporeal circuit' [ISRCTN58520610] (see http://www.controlled-trials.com/ISRCTN58520610). |
| Ethics approval(s) | Commissie Medische Ethiek Van de Universitair Ziekenhuizen Kuleuven gave approval in January 2009 |
| Health condition(s) or problem(s) studied | Kidney disease |
| Intervention | 1. Continuous veno-venous haemofiltration (CVVH) mode without heparin administration 2. Continuous veno-venous haemodiafiltration (CVVHDF) mode without heparin administration 3. Continuous veno-venous haemodiafiltration (CVVHDF) mode with heparin administration Each patient will be treated by a maximum of 4 filters (surface treated [ST] and non-ST). |
| Intervention type | Drug |
| Pharmaceutical study type(s) | |
| Phase | Phase IV |
| Drug / device / biological / vaccine name(s) | Prismaflex ST150, Prismaflex M150 |
| Primary outcome measure | Filter lifespan, defined as the time period between patients connection and filter disconnection. Filter clotting will be detected by following transmembrane pressure (TMP) and Filter Pressure Drop (FPD). |
| Secondary outcome measures | Follow-up of adverse events (AE)/serious adverse events (SAE), assessed throughout the treatment. |
| Overall study start date | 16/02/2009 |
| Completion date | 16/02/2010 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | Both |
| Target number of participants | 18 |
| Key inclusion criteria | 1. Patients requiring continuous renal replacement therapy (CRRT) 2. Patients aged 18 and over, either sex 3. Patients weighing 30 - 120 kg 4. Patients having signed a written consent (informed consent) to participate in the study or, in case the patient is unable to understand and/or sign the consent form, written consent from a relative or, failing which, a person of trust |
| Key exclusion criteria | 1. Suspicion of heparin-induced thrombocytopenia 2. Pregnancy 3. Patients requiring therapeutic anticoagulation for other indications e.g. valvular surgery or extracorporeal ventricular assist devices 4. Patients under guardianship 5. Patients anticipated to require transportation outside the unit for diagnostic or therapeutic procedures in the coming first week. These patients can eventually be included in a later more stable phase. 6. Current enrolment in another trial which could impact the successful completion of this study 7. Unconscious patients for whom no relative or person of trust can give consent for treatment. In the absence of any relative or person of trust, the patient in question cannot be included in the study. 8. Patients with high bleeding risk according to investigator and that cannot be treated with heparin. These patients should not be included in the therapy group continuous veno-venous haemodiafiltration (CVVHDF) with heparin administration. |
| Date of first enrolment | 16/02/2009 |
| Date of final enrolment | 16/02/2010 |
Locations
Countries of recruitment
- Belgium
Study participating centre
Dept of Intensive Care
Leuven
3000
Belgium
3000
Belgium
Sponsor information
Gambro Industries (France)
Industry
Industry
7, Avenue Lionel Terray
Meyzieu
69883
France
"ROR" |
https://ror.org/01mgtdr23 |
|---|
Funders
Funder type
Industry
Gambro Industries (France)
No information available
Results and Publications
| Intention to publish date | |
|---|---|
| Individual participant data (IPD) Intention to share | No |
| IPD sharing plan summary | Not provided at time of registration |
| Publication and dissemination plan | Not provided at time of registration |
| IPD sharing plan |
